April 2013 in “Cancer Research” A botanical extract was found to be a safe treatment that may prevent hair loss in chemotherapy patients.
August 2018 in “Journal of the American Academy of Dermatology” Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.
February 2026 in “Indian Journal of Dermatology” Upadacitinib may effectively treat twenty-nail dystrophy without causing pain.
June 2025 in “Clinical Cancer Research” Scalp cooling can effectively prevent hair loss during chemotherapy in pregnancy.
August 2023 in “Frontiers in Oncology” New drugs and therapies targeting specific pathways show promise in treating advanced prostate cancer.
88 citations
,
July 2014 in “Journal of the American Academy of Dermatology” Targeted cancer therapies often cause skin reactions, so dermatologists must manage these effects.
4 citations
,
June 2025 in “MedComm” PROTACs show promise for cancer treatment, but designing them effectively is challenging.
September 2025 in “PubMed” Prevent persistent hair loss after chemotherapy with scalp cooling and early minoxidil use.
49 citations
,
March 2017 in “Journal of the American Academy of Dermatology” Tofacitinib caused significant hair regrowth in adolescents with alopecia universalis who didn't respond to other treatments.
1 citations
,
January 2024 in “Curēus” Upadacitinib significantly improved a man's severe scalp condition when other treatments failed.
1 citations
,
June 2007 in “Journal of Clinical Oncology” Weekly bicalutamide is safe and effective, with 50 mg/week recommended.
May 2025 in “JEADV Clinical Practice” Tofacitinib and methotrexate successfully treated a woman's severe skin, joint, and hair loss issues.
1 citations
,
May 2006 in “Expert Opinion on Therapeutic Patents” No FDA-approved treatments for chemotherapy-induced hair loss existed in 2006; more research was needed.
11 citations
,
January 2018 in “Acta dermato-venereologica” Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.
June 2025 in “British Journal of Dermatology” Ruxolitinib helped a woman with a genetic mutation regrow her hair and improved her health.
3 citations
,
January 2018 in “Biomedical dermatology” Green tea extract helps prevent cell death and supports cell survival in hair cells exposed to a chemotherapy drug.
September 2023 in “Journal of the American Academy of Dermatology” CTP-543 is generally safe for treating alopecia areata.
4 citations
,
January 1987 in “Beiträge zur Onkologie/Contributions to oncology” Adriamycin and ifosfamide together work best for advanced soft tissue sarcomas.
January 2016 in “대한피부과학회지” Bortezomib chemotherapy can cause temporary skin rashes.
4 citations
,
May 2019 in “Sultan Qaboos University Medical Journal” Tofacitinib helped regrow hair in a patient with severe hair loss and improved their quality of life without side effects.
25 citations
,
November 2022 in “British journal of dermatology/British journal of dermatology, Supplement” Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.
2 citations
,
August 2013 in “British Journal of Dermatology” Chemotherapy improved a girl's painful foot condition linked to pachyonychia congenita.
January 2025 in “Dermatologic Therapy” Baricitinib works better for alopecia areata in patients not previously treated with tofacitinib.
7 citations
,
January 2023 in “Anti-Cancer Drugs” Early diagnosis and treatment of EGFR inhibitor-induced folliculitis decalvans can prevent permanent hair loss.
September 2023 in “Journal of The American Academy of Dermatology” Baricitinib shows promise in treating severe hair loss.
3 citations
,
October 1994 in “Journal of Labelled Compounds and Radiopharmaceuticals” Scientists made a carbon-14 labeled version of a drug with a 48% yield and over 99% purity.
70 citations
,
April 2016 in “Experimental Dermatology” A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.
July 2024 in “Journal of Investigative Dermatology” PH-762 shows promise in treating skin cancer by effectively targeting and silencing PD-1 in tumors with minimal side effects.
September 2022 in “XXXIX Congresso Brasileiro de Reumatologia” Tofacitinib may effectively treat skin symptoms in difficult cases of dermatomyositis.
January 2012 in “Journal of Clinical Medicine in Practice” The treatment is safe and effective for elderly patients with advanced non-small-cell lung cancer.